ArticleVirchows Archiv : an international journal of pathology2020
Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
Article in Virchows Archiv : an international journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The Survival Benefits of Chemotherapy for Undifferentiated Carcinoma With Osteoclast-Like Giant Cells of Pancreas: A Retrospective Analysis and Individual Participant Data Meta-Analysis.Cancer medicine · 2025Pooled it
- Clinical characteristics and survival outcomes for undifferentiated carcinoma with/without osteoclast-like giant cells of the pancreas.Updates in surgery · 2026Article
- Pancreatic ductal adenocarcinoma and its subtypes: clinical relevance of histopathology and molecular characterization, integrating the key updates of the 2026 WHO classification.Virchows Archiv : an international journal of pathology · 2026Review
- Review
- Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal adenocarcinoma.Frontiers in oncology · 2026Article
- Undifferentiated Carcinoma with Osteoclast-Like Giant Cells Associated with CarcinomaSurgical case reports · 2026Article
- A current knowledge of the undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: a narrative review.Journal of gastrointestinal oncology · 2025Review
- Article
- Characterization of undifferentiated carcinomas of the pancreas with and without osteoclast-like giant cells.JNCI cancer spectrum · 2025Article
- Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a rare case report and review of the literature.Frontiers in surgery · 2025Article
- Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: An individual participant data meta-analysis.Annals of hepato-biliary-pancreatic surgery · 2024Review
- Article
- Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.International journal of molecular sciences · 2024Article
- Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a narrative review.Frontiers in oncology · 2024Review
- A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?Therapeutic advances in medical oncology · 2024Review
- Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: a case report.Journal of medical case reports · 2023Article
- Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.Japanese journal of clinical oncology · 2023Review
- Case report: Pathological and genetic features of pancreatic undifferentiated carcinoma with osteoclast-like giant cells.Pathology oncology research : POR · 2023Article
- Undifferentiated Pancreatic Carcinomas, Clinical Features and Therapeutic Options: What We Know.Cancers · 2022Review
- Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer.Scientific reports · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.